Characterization of Pediatric Acute Myeloid Leukemia With t(7;12)(q36;p13)
Authors:
Open Access
- 7 November 2024
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 63 (11)
Abstract
Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is a recurrent translocation in AML in infants or very young children and was recently included in the World Health Organization (WHO) Classification of Hematolymphoid Tumors. AML with t(7;12) is reported to involve MNX1 and ETV6 signaling; however, the mechanism of leukemogenesis is not well understood, and the presence of MNX1::ETV6 fusion transcripts has only been confirmed in approximately 50% of cases. In contrast, high expression of MNX1 has been seen in all investigated cases. In this study, we investigated the clinical as well as biological characteristics of 12 pediatric AML with t(7;12) and performed whole transcriptome (WTS) and whole genome sequencing (WGS) on six of these. There was no significant difference in event‐free survival or overall survival of these t(7;12) AML patients compared with other AML in the same age group. Interestingly, WTS identified several fusion transcripts involving ETV6 but not together with MNX1. WGS identified the genomic breakpoints and revealed that a common fusion partner on chromosome 7 was NOM1. Principal component analysis (PCA) of the WTS data showed that all t(7;12) AML cases cluster together, separate from all other pediatric AML subtypes; all cases had high expression of MNX1, MNX1‐AS1, and MNX1‐AS2. Hence, t(7;12) AML, despite expressing different fusion transcripts and with varying translocation breakpoints, constitutes a phenotypically homogenous subgroup. This underlines that the leukemia‐driving event most likely is ectopic expression of MNX1 and that this therefore should be the defining Classifying criteria of this type of AML.Keywords
Funding Information
- Stiftelsen Assar Gabrielssons Fond
- Cancerfonden
- Barncancerfonden
- Västra Götalandsregionen
This publication has 29 references indexed in Scilit:
- An induced pluripotent stem cell t(7;12)(q36;p13) acute myeloid leukemia model shows high expression of MNX1 and a block in differentiation of the erythroid and megakaryocytic lineagesInternational Journal of Cancer, 2022
- MNX1 promotes cell proliferation and activates Wnt/β‐catenin signaling in colorectal cancerCell Biology International, 2019
- Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: Data from Nordic Society for Pediatric Hematology and Oncology (NOPHO‐AML) and review of the literatureGenes, Chromosomes and Cancer, 2018
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastomaCancer Letters, 2015
- ETV6 fusion genes in hematological malignancies: A reviewLeukemia Research, 2012
- Three-way complex translocations in infant acute myeloid leukemia with t(7;12)(q36;p13): The incidence and correlation of a HLXB9 overexpressionCancer Genetics and Cytogenetics, 2009
- High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9Genes, Chromosomes and Cancer, 2006
- Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemiaGenes, Chromosomes and Cancer, 2003
- t(7;12)(q36;p13), a new recurrent translocation involvingETV6 in infant leukemiaGenes, Chromosomes and Cancer, 2000